Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 8
Submit an article Journal homepage
478
Views
97
CrossRef citations to date
0
Altmetric
Special Report

Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques

Alex J O’Neill School of Biochemistry and Microbiology, Antimicrobial Research Centre,University of Leeds, Leeds, LS2 9JT, UK. [email protected]
&
Ian Chopra School of Biochemistry and Microbiology, Antimicrobial Research Centre,University of Leeds, Leeds, LS2 9JT, UK. [email protected]
Pages 1045-1063 | Published online: 24 Feb 2005

Bibliography

  • LEVY SB: The Antibiotic Paradox: How Miracle Drugs are Destroying the Miracle. Press, New York, USA (1992).
  • JOHNSTON N: Seeking superbug-busters. Mod. Drug Discov. (2002) 5:34–36.
  • PROJAN SJ: Why is big Pharma getting out of antibacterial drug discovery? Carr: Opin. Microbia (2003) 6:427–430.
  • PROJAN SJ: New (and not so new) antibacterial targets - from where and when will the novel drugs come? Carr: Opin. Pharmaca (2002) 2:513–522.
  • CHOPRA I, HESSE L, O'NEILL AJ: Discovery and development of new antibacterial drugs. In: Trend in Drug Research III: proceedings of the 13th Noordwhkerhout-carnerino symposium (Vol. 32). Van der Goot H (Ed.) Elsevier Press, Amsterdam, Holland (2002):213–225.
  • PROJAN SJ, YOUNGMAN PJ:: new solutions badly needed. Curr. Opin. Microbia (2002) 5:463–465.
  • CHOPRA I, HESSE L, O'NEILL AJ: Exploiting current understanding of antibiotic action for discovery of new drugs. Microbia (2002) 92:4S–15S.
  • FRANCO CMM, COUTINHO LEL: of novel secondary metabolites.Crit. Rev Biotechnol (1991) 11:193–276.
  • DOUGHERTY TJ, PROJAN SJ: Microbial Genomics and Drug Discovery Marcel Dekker, New York, USA (2003).
  • ••An excellent overview of molecularapproaches for antimicrobial drug discovery in the post-genomic era.
  • CHAN PF, MACARRON R, PAYNE DJ, ZALACAIN M, HOLMES DJ: Novel antibacterials: a genomics approach to drug. Curr. Drug Targets Infect. Disord. (2002) 2:291–308.
  • •Provides a useful discussion of genomics/ bioinformatics in the drug discovery process.
  • SILVER L, BOSTIAN K: Screening of natural products for antimicrobial agents..Microbia Infect. Dis. (1990) 9:455–461.
  • GOOTZ TD: Discovery and development of new antimicrobial agents. Clin. Microbia Rev (1990) 3:13–31.
  • BILLSTEIN SA: How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimicrob. Agents Chemother. (1994) 38:2679–2682.
  • BEAM TR, GILBERT DN, KUNIN CM: General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. (1992) 15:S5–S32.
  • TUNKEL AR, SCHELD WM: of therapy in animal models to bacterial infection in human disease. Infect. Dis. Clin. North Am. (1989) 3:441–459.
  • FOOD AND DRUG: Guideline and Format of the Microbiology Section of an Application (Docket No. 85D-0245), US Department of Health and Human Services (1990).
  • Antibiotics in Laboratory Medicine V Lorian (Ed.), Williams & Wilkins, Baltimore, USA (1996).
  • O'NEILL AJ, OLIVA B, STOREY C et al: RNA polymerase inhibitors with activity against rifampin-resistant mutants of aureus. Antimicrob. Agents Chemother. (2000) 44:3163–3166.
  • OLIVA B, MILLER K, CAGGIANO N al.: Antimicrobial properties and mechanisms of action of novel quinoline-indole agents possessing potent anti-staphylococcal activity. Antimicrob. Agents Chemother. (2003) 47:458–466.
  • EVANS SM, CASARTELLI A, HERREROS E et al.: Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential. Toxica Vitro (2001) 15:579–584.
  • GE Y, DIFUNTORUM S, TOUAMI S et al.: In vitro antimicrobial activity of GSQ1530, a new heteroaromatic polycyclic compound. Antimicrob. Agents Chemother. (2002) 46:3168–3174.
  • PAYNE DJ, MILLER WH, BERRY V et al.: Discovery of a novel and potent class of FabI-directed antibacterial agents.. Agents Chemother. (2002) 46:3118–3124.
  • IANDOLO JJ, WORRELL V, GROICHER KH et al.: Comparative analysis of the genomes of the temperate bacteriophages phi 11, phi 12 and phi 13 of Staphylococcus aureus 8325. Gene (2002) 289:109–118.
  • FAIRWEATHER N, KENNEDY S, FOSTER TJ, KEHOE M, DOUGAN G: Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus. Infect. Inman. (1983) 41:1112–1117.
  • NIKAIDO H: Multiple antibiotic resistanceand efflux. Carr. Opin. Microbia (1998) 1:516–523.
  • SULAVIK MC, HOUSEWEART C, CRAMER C et al.: Antibiotic susceptibility profiles of Escherichia coil strains lacking multidrug efflux pump genes. Arkin-nu-ob. Agents Chemother. (2001) 45:1126–1136.
  • SUKUPOLVI S, VAARA M: Salmonella gphimurium and Escherichia coil mutants with increased outer membrane permeability to hydrophobic compounds. Biochim. Biophys. Acta (1989) 988:377–387.
  • AUSTIN EA, GRAVES JF, HITE LA, PARKER CT, SCHNAITMAN CA: Genetic analysis of lipopolysaccharide core biosynthesis by Escherichia coil K-12: insertion mutagenesis of the rfa locus. (1990) 172:5312–5325.
  • CLARK D: Novel antibiotic hypersensitive mutants of Escherichia colt. Genetic mapping and chemical characterization. Microbia Lett. (1984) 21:189–195.
  • HEISLER LM, SUZUKI H, LANDICK R, GROSS CA: Four contiguous amino acids define the target for streptolydigin resistance in the Beta subunit of Escherichia coil RNA Polymerase. Biol. Chem. (1993) 268:25369–25375.
  • LING L, DAVEY ME, SCHUMACHER T et al.: Novel permeable strains of E. coliwith improved properties for screening and mechanism of action studies. 43rd Interscience Conference of Antimicrobial Agents & Chemotherapy(2003) (Abstract 1467).
  • KOETH LM, KING A, KNIGHT H et al:Comparison of cation-adjusted Mueller-Hinton broth with Iso-Sensitest broth for the NCCLS broth microdilution method. .1. Antimicrob. Chemother: (2000) 46:369–376.
  • ANDREWS JM: Determination of minimum inhibitory concentrations. J.Antimicrob. Chemother: (2001) 48:5–16.
  • WHEAT PF: History and development of antimicrobial susceptibility testing methodology. I Antimicrob. Chemother: (2001) 48 (Suppl. 1):1–4.
  • NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (4th Edn). Approved standard M7-A4 National Committee for Clinical Laboratory Standards, Villanova,, USA (1997).
  • O'NEILL AJ, BOSTOCK J, MOITA A, CHOPRA I: Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. .1. Antimicrob. Chemother: (2003) 50:839–848.
  • SLATER K: Cytotoxicity tests for high-throughput drug discovery. Car: Opin. Biotechnol (2001) 12:70–74.
  • BUGELSKI PJ, ATIF U, MOLTON S et al.: A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology. Pharm. Res. (2000) 17:1265–1272.
  • DUNMAN PM, PROJAN SJ: Expression profiling uses in antibacterial chemotherapy development. In: Microbial Cenomics and Drug Discovery TJ Dougherty, SJ Projan (Eds), Marcel Dekker, New York, USA (2003).
  • CROWTHER DJ: Applications of microarrays in the pharmaceutical industry.. Opin. Pharmaca (2002) 2:551–554.
  • GOLLAPUDI BB, KRISHNA G: Practical aspects of mutagenicity testing strategy: an industrial perspective. Mutat. Res. (2000) 455:21–28.
  • ASHBY J, TENNANT RW: Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the US NCl/ NTP. Mutat. Res. (1988) 204:17–115.
  • ASHBY J, PATON D: The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures. Mutat. Res. (1993) 286:3–74.
  • MORTELMANS K, ZEIGER E: The Ames Salmonellalmicrosome mutagenicity assay. Mutat. Res. Fundam. Ma. Mech. Mutagen (2000) 455:29–60.
  • GOCKE E: Mechanism of quinolone mutagenicity in bacteria. Mutat. Res. (1991) 248:135–143.
  • POWER EG, PHILLIPS I: Correlation between umuCinduction and Salmonella mutagenicity assay for quinolone antimicrobial agents. FEMS Microbia Lett. (1993) 112:251–254.
  • SHIMADA H, ITOH S, HATTORI C, TADA S, MATSUURA Y: Mutagenicity of the new quinolone antibacterial agent levofloxacin. Arzneimittelforschung (1992) 43:378–385.
  • BEABER JW, HOCHHUT B, MK: SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature (2004) 427:72–74.
  • PURVES D, HARVEY C, TWEATS D, LUMLEY CE: Genotoxicity testing: current and strategies used by the pharmaceutical industry. Mutagenesis (1995) 10:297–312.
  • GARRIOTT ML, PHELPS JB, HOFFMAN WP: A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity. Mutat. Res. (2002) 517:123–134.
  • KISKINIS E, SUTER W, HARTMANN A: throughput Comet assay using 96-well plates. Mutagenesis (2002) 17:37–43.
  • SUCHLAND RJ, GEISLER WM, STAMM WE: Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob. Agents Chemother: (2003) 47:636–642.
  • KING A: Recommendations for susceptibility tests on fastidious organisms and those requiring special handling.. Chemother. (2001) 48\(Suppl. 1):77–80.
  • MULLIGAN MJ, COBBS CG: Bacteriostatic versus bactericidal activity. Infect. Dis. Clio. North Am. (1989) 3:389–398.
  • SCHOLAR EM, PRATT WB: The Antimicrobial Drugs. Oxford University Press, New York, USA (2000).
  • OLIVA B, O'NEILL AJ, WILSON JM, O'HANLON PJ, CHOPRA I: properties and mode of action of the pyrrothine holomycin.. Agents Chemother. (2001) 45:532–539.
  • HILLIARD JJ, GOLDSCHMIDT RM, LICATA L, BAUM EZ, BUSH K: Multiple of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob. Agents Chemother: (1999) 43:1693–1699.
  • SHEN AY, CHEN CP, ROFFLER S: A chelating agent possessing cytotoxicity and antimicrobial activity: 7-morpholinomethy1-8-hydroxyquinoline. Sci. (1999) 64:813–825.
  • RASMUSSEN B, NOLLER HF, DAUBRESSE G et al.: Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome. Antimicrob. Agents Chemother. (1991) 35:2306–2311.
  • RODIONOV DG, ISHIGURO EE: Direct between overproduction of guanosine 3',Y-bispyrophosphate (ppGpp) and penicillin tolerance in Escherichia coli (1995) 177:4224–4229.
  • TUOMANEN E, TOMASZ A: Induction autolysis in nongrowing Escherichia coll. (1986) 167:1077–1080.
  • CARSON CF, MEE BJ, RILEY TV: Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrob. Agents Chemother: (2002) 46:1914–1920.
  • JOHNSTON MD, HANLON GW, DENYER SP, LAMBERT RJ: Membrane damage to bacteria caused by single and combined biocides. AppL Microbia (2003) 94:1015–1023.
  • OLIVA B, O'NEILL AJ, MILLER K, STUBBINGS W, CHOPRA I: Antistaphylococcal activity and mode of action of clofazimine. I Antimicrob. Chemother. (2004) 53:435–440.
  • PORTER EA, WEISBLUM B, SH: Mimicry of host-defense peptides by unnatural oligomers: antimicrobial beta-peptides. Jim. Chem. Soc. (2002) 124:7324–7330.
  • DIXON RA, CHOPRA I: Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in Escherichia coll. I Antimicrob. Chemother: (1986) 18:557–563.
  • LING LL, LIANG X, PUYANG X, ARVANITES A, OPPERMAN T: Rapid elimination of compounds acting through non-specific membrane perturbation mechanisms. 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy Chicago, USA (2003) (Abstract 1469).
  • STUBBINGS WJ, BOSTOCK JM, INGHAM E, CHOPRA I: Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coll. Antimicrob. Chemother. (2004) 54:139–143.
  • ODENHOLT I: Pharmacodynamic effects of subinhibitory antibiotic concentrations. hat. Antimicrob. Agents (2001) 17:1–8.
  • O'GRADY F, LAMBERT HP, FINCH RG, GREENWOOD D: Antibiotic and Chemotherapy Churchill Livingstone, Edinburgh, Scotland (1997).
  • GEORGE RH: The influence of protein binding on the antistaphylococcal activity of antibiotics. Antimicrob. Chemother: (1986) 17:539–540.
  • ROYCHOUDHURY S, BRILL JL, LU WP et al: Development of a screening assay to measure the loss of antibacterial activity in the presence of proteins: its use in optimizing compound structure. Bioma Screen (2003) 8:555–558.
  • VERBIST L: The antimicrobial activity of fusidic acid. I. Antimicrob. Chemother. (1990) 25:1–5.
  • MeNAMARA PJ, TRUEB V, K: Protein binding of ceftriaxone in extravascular fluids. I Pharm. Sci. (1988) 77:401–404.
  • DECROIX MO, ZINI R, JC, TILLEMENT JP: Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs. Biochem. Pharmaca (1988) 37:2807–2814.
  • BERNAREGGI A, BORGONOVI M, DEL FAVERO A, ROSINA R, GAVANAGHI L: Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers. Eur. J. Drug Metab. Pharmacokinet. (1991) (Spec. No. 3):256–260.
  • CERI H, OLSON ME, STREMICK C et al.: The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofllms.j Clio. Microbia (1999) 37:1771–1776.
  • GRAY CP, KECK W: Genomic strategies in antibacterial drug discovery. In: Microbial Genomics and Drug Discovery Dougherty, SJ Projan (Eds), Marcel Dekker, New York, USA (2003).
  • STRUTHERS JK: The use of a continuous culture system to study the antimicrobial susceptibility of bacteria in biofilm. In: Antibiotic Resistance Methods and Protocols. SH Gillespie (Ed.), Humana, Totowa, USA (2000).
  • HODGSON AE, NELSON SM, MR, GILBERT P: A simple in vitro model for growth control of bacterial biofilms. I Appl. Bacteria (1995) 79:87–93.
  • BUDHANI RK, STRUTHERS JK: The use of Sorbarod biofilms to study the antimicrobial susceptibility of a strain of Streptococcus pneumoniae. Antimicrob. Chemother. (1997) 40:601–602.
  • TUCKMAN M, PETERSEN PJ, PROJAN SJ: Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. (2000) 6:277–282.
  • BARLOW M, HALL BG: Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC P-lactamase. Genetics (2003) 164:23–29.
  • LURIA SA, DELBRUCK M: Mutations of bacteria from virus sensitivity to virus resistance. Genetics (1943) 28:491–511.
  • O'NEILL AJ, COVE JH, CHOPRA I: Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus. .1. Antimicrob. Chemother. (2001) 47:647–650.
  • MOBASHERY S, AZUCENA EF: Bacterial antibiotic resistance. In: Nature Encyclopedia of IRO Sciences Nature Publishing Group, London (1999)
  • MILLER K, O'NEILL AJ, CHOPRA I: Response of Escherichia coil hypermutators to selection pressure with antimicrobial agents from different classes. J. Antimicrob. Chemother: (2002) 49:925–934.
  • SCHMID MB: Microbial genomics - new targets, new drugs. Expert Opin. Ther. Targets (2001) 5:465–475.
  • INCE D, ZHANG X, SILVER LC, HOOPER DC: Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother: (2003) 47:274–282.
  • O'NEILL AJ, CHOPRA I: Use of mutator strains for characterization of novel antimicrobial agents. Antimicrob. Agents Chemother: (2001) 45:1599–1600.
  • CHOPRA I, O'NEILL AJ, MILLER K: The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. UpdaL (2003) 6:137–145.
  • ZHAO XL, DRLICA K: Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clio. Infect. Dis. (2001) 33:S147–S156.
  • ANDERSSON DI, LEVIN BR: The biological cost of antibiotic resistance. Curr. Opin. Microbia (1999) 2:489–493.
  • LENSKI RE: The cost of antibiotic resistance - from the perspective of a bacterium. Ciba Found. Symp. (1997) 207:131–140.
  • HURDLE JG, O'NEILL AJ, INGHAM E, FISHWICK C, CHOPRA I: Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modelling techniques. Antimicrob. Agents Chemother. (2004) (In press).
  • NILSSON Al, BERG OG, ASPEVALL 0, KAHLMETER G, ANDERSSON DI: Biological costs and mechanisms of fosfomycin resistance in Escherichia coll. Antimicrob. Agents Chemother. (2003) 47:2850–2858.
  • BAND OW JE, BROTZ H, LIO, LABISCHINSKI H, HECKER M: Proteomic approach to understanding antibiotic action. Antimicrob. Agents Chemother: (2003) 47:948–955.
  • DOUGHERTY TJ: In: Microbial Genomics and Drug Discovery TJ Dougherty, SJ Projan (Eds), Marcel Dekker, New York, USA (2003).
  • OLIVA B, MAIESE WM, M, BORDERS DB, CHOPRA I: Mode of action of the cyclic depsipeptide antibiotic LL-A0341 13–1 and partial characterization of a Staphylococcus aureus mutant resistant to the antibiotic. Antimicrob. Chemother: (1993) 32:817–830.
  • BANERJEE A, DUBNAU E, A et al.: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science (1994) 263:227–230.
  • DELGADO MA, RINTOUL MR, FARIAS RN, SALOMON RA: Escherichia coil RNA polymerase is the target of the cyclopeptide antibiotic microcin J25. (2001) 183:4543–4550.
  • SIVASUBRAMANIAN N, JAYARAMAN R: Mapping of two transcription mutations 0.1nI and drill) conferring thiolutin resistance, adjacent to dnaZ and rho in Escherichia coil Ma Gen. Genet. (1980) 180:609–615.
  • LUCHANSKY JB, PATTEE PA: Isolation of transposon Tn551 insertions near chromosomal markers of interest in Staphylococcus aureus Bacteria (1984) 159:894–899.
  • BELANGER AE, LAI A, MA, LEBLANC DJ: PCR-based ordered genomic libraries: A new approach to drug target identification for Streptococcus pneumonia e Antimicrob. Agents Chemother. (2002) 46:2507–2512.
  • UTAIDA S, DUNMAN PM, MACAPAGAL D et Genome-wide transcriptional profiling of the response of Staphylococcus aureusto cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiology (2003) 149:2719–2732.
  • PHADTARE S, KATO I, INOUYE M: DNA microarray analysis of the expression profile of Escherichia coliin response to treatment with 4,5-dihydroxy-2-cyclopenten-l-one. Bacteria (2002) 184:6725–6729.
  • SHAW KJ, MILLER N, LIU X et at Comparison of the changes in global gene expression of Escherichia collinduced by four bactericidal agents. .1 Ma Microbia Biotechna (2003) 5:105–122.
  • EVERS S, DI PADOVA K, MEYER M et al.: Mechanism-related changes in the gene transcription and protein synthesis patterns of Haemophilus influenzae after treatment with transcriptional and translational inhibitors. Proteomics (2001) 1:522–544.
  • SINGH VK, JAYASWAL RK, WILKINSON BJ: Cell wall-active antibiotic induced proteins of Staphylococcus aureus identified using a proteomic approach. FEMS Microbia Lett. (2001) 199:79–84.
  • SABINA J, DOVER N, TEMPLETON LJ et al.: Interfering with different steps of protein synthesis explored by transcriptional profiling of Escherichia coif K-12. (2003) 185:6158-6170.
  • GMUENDER H, KURATLI K, DI PADOVA K et al.: Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res. (2001) 11:28–42.
  • CHATTERJEE PK, STERNBERG NL: A general genetic approach in Escherichia coil for determining the mechanism(s) of action of tumoricidal agents: application to DMP 840, a tumoricidal agent. Proc. Nati Acad. Sci. USA (1995) 92:8950–8954.
  • HUANG J, HE J, SHEN Wet al.: A novel approach for studying antibiotic mode of action and resistance using a Staphylococcus aureus ORF expression library. 43rd Interscience Conference of Antimicrobial Agents and Chemotherapy Chicago, USA (2003) (Abstract 1468).
  • APFEL CM, LOCHER H, EVERS S et al.: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. (2001) 45:1058–1064.
  • DEVITO JA, MILLS JA, LIU VG et al.: An array of target-specific screening strains for antibacterial discovery. Nat. Biotechna (2002) 20:478–483.
  • FAN F, LUNSFORD RD, SYLVESTER D et al.: Regulated ectopic expression and allelic-replacement mutagenesis as a method for gene essentiality testing in Staphylococcus aureus. Plasmid (2001) 46:71–75.
  • ZHANG L, FAN F, PALMER LM et al: Regulated gene expression in Staphylococcus aureus for identifying conditional lethal and antibiotic mode of action. Gene (2000) 255:297–305.
  • CHAN PF, O'DWYER KM, PALMER LM et al.: Characterization of a novel fucose-regulated promoter (P1) suitable for gene essentiality and antibacterial mode-of-action studies in Streptococcus pneumoniae. (2003) 185:2051–2058.
  • YIN D, FOX B, LONETTO ML et at.: Identification of antimicrobial targets using a comprehensive genomic approach. Pharmacogenomics (2004) 5:101–113.
  • FORSYTH RA, HASELBECK RJ, OHLSEN KL et al.: A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Ma Microbia (2002) 43:1387–1400.
  • GOOD L: Diverse antisense mechanisms and applications. Cell. Ma Life Sci. (2003) 60:823–824.
  • GOOD L, NIELSEN PE: Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. Nat. Biotechna (1998) 16:355–358.
  • TAO J, WENDLER P, CONNELLY G et al.: Drug target validation: lethal infection blocked by inducible peptide. Proc. Nati Acad. Sci. USA (2000) 97:783–786.
  • STUBBINGS W, INGHAM E, I: Deletion of the multiple drug efflux pump AcrAB in Escherichia coil prolongs the postantibiotic effect. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, USA (2002).
  • TENOVER FC: Development and spread of bacterial resistance to antimicrobial agents: an overview. Clio. Infect. Dis. (2001) 33\(Suppl. 3):5108–5115.
  • CLARK NM, HERSHBERGER E, ZERVOSC MJ, LYNCH JP 3rd: Antimicrobial resistance among Gram-positive organisms in the intensive care unit. Car: Opin. Crit. Care (2003) 9:403–412.
  • CLARK NM, PATTERSON J, LYNCH JP 3rd: Antimicrobial resistance among Gram-negative organisms in the intensive care unit. CWT. Opin. Grit. Care (2003) 9:413–423.
  • PUBLIC HEALTH LABORATORY SERVICE: Antimicrobial resistance in 2000: England & Wales: Public Health Laboratory Service, London (2002).
  • DRLICA K: Mechanism of fluoroquinolone action. Carr: Opin. Microbial. (1999) 2:504–508.
  • BIANCHI AA, BANEYX F: Stress responses as a tool to detect and characterize the mode of action of antibacterial agents.. Environ. Microbial. (1999) 65:5023–5027.
  • SHAPIRO E, BANEYX F: Stress-based identification and classification of antibacterial agents: second-generation Escherichia co/ireporter strains and optimization of detection. Antlinicrob. Agents Cheinother. (2002) 46:2490–2497.
  • OH JT, CAJAL Y, SKOWRONSKA EM et al.: Cationic peptide antimicrobials induce selective transcription of inicFand osinY in Escherichia coll. Biochim. Biophys. Acta (2000) 1463:43–54.
  • FISCHER HP, BRUNNER NA, WIELAND B et al.: Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. Genome Res. (2004) 14:90–98.
  • SUN D, COHEN S, MANI N, MURPHY C, ROTHSTEIN DM: A-specific cell based screening system detect bacterial cell wall inhibitors. .1. Antibiot. (Tokyo) (2002) 55:279–287.
  • CHOPRA I: Antibiotics. In: Nature Encyclopedia of Life Sciences. Nature Publishing Group, London (June 2001). http://www.els.net/

Websites

  • http://www.the-scientist.com/images/200 1 /pdfs/cytol_010305.pdf detailing the suppliers of cytotoxicity reagents.
  • http://www.the-scientist.com/images/200 1/pdfs/cyto2_010305.pdf detailing the suppliers of cytotoxicity reagents.
  • http://www.atcc.org/ LGC Promochem website.
  • http://www.hpa.org.uldsrmd/ div_cdmssd_nctc/index.htm Health Protection Agency website.
  • http://www.nccls.org NCCLS website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.